Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Stanley B. Cohen; Paul Emery; Maria W. Greenwald; Maxime Dougados; Richard A. Furie; Mark C. Genovese; Edward C. Keystone; James E. Loveless; Gerd-Rüdiger Burmester; Matthew W. Cravets; Eva W. Hessey; Timothy Shaw; Mark C. Totoritis;

doi:10.1002/art.22025

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Arthritis & Rheumatism ◽

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718325315.793492809 ◽

2014 ◽

Author(s):

Ronald van Vollenhoven

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate

APLAR Journal of Rheumatology ◽

10.1111/j.1479-8077.2007.00248.x ◽

2007 ◽

Vol 10 (1) ◽

pp. 9-16 ◽

Cited By ~ 38

Author(s):

Ho-Youn KIM ◽

Soo-Kon LEE ◽

Yeong Wook SONG ◽

Dae-Hyun YOO ◽

Eun-Mi KOH ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase Iii ◽

Double Blind ◽

Subcutaneous Injections ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Necrosis Factor

Download Full-text

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Critical Care Medicine ◽

10.1097/00003246-200103000-00006 ◽

2001 ◽

Vol 29 (3) ◽

pp. 503-510 ◽

Cited By ~ 205

Author(s):

Edward Abraham ◽

Pierre-François Laterre ◽

Jorge Garbino ◽

Susan Pingleton ◽

Thomas Butler ◽

...

Keyword(s):

Septic Shock ◽

Severe Sepsis ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Receptor ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Necrosis Factor

Download Full-text

Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

Arthritis & Rheumatism ◽

10.1002/art.27348 ◽

2010 ◽

Vol 62 (4) ◽

pp. 917-928 ◽

Cited By ~ 76

Author(s):

Joel Kremer ◽

Christopher Ritchlin ◽

Alan Mendelsohn ◽

Daniel Baker ◽

Lilianne Kim ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

Arthritis & Rheumatism ◽

10.1002/art.33353 ◽

2012 ◽

Vol 64 (2) ◽

pp. 360-370 ◽

Cited By ~ 41

Author(s):

P. P. Tak ◽

P. J. Mease ◽

M. C. Genovese ◽

J. Kremer ◽

B. Haraoui ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Inhibitor ◽

Phase Iii ◽

Inadequate Response ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Parallel Group ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

The Lancet ◽

10.1016/s0140-6736(09)60506-7 ◽

2009 ◽

Vol 374 (9685) ◽

pp. 210-221 ◽

Cited By ~ 338

Author(s):

Josef S Smolen ◽

Jonathan Kay ◽

Mittie K Doyle ◽

Robert Landewé ◽

Eric L Matteson ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Tumour Necrosis Factor Α ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T)

Modern Rheumatology ◽

10.1080/14397595.2018.1452345 ◽

2018 ◽

Vol 29 (2) ◽

pp. 306-313

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Masayoshi Harigai ◽

Hisashi Yamanaka ◽

Toshikazu Nakano ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Active Rheumatoid Arthritis ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Multicenter Phase ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Arthritis & Rheumatology ◽

10.1002/art.40753 ◽

2019 ◽

Vol 71 (4) ◽

pp. 599-611 ◽

Cited By ~ 54

Author(s):

Atul Deodhar ◽

Denis Poddubnyy ◽

Cesar Pacheco‐Tena ◽

Carlo Salvarani ◽

Eric Lespessailles ◽

...

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Erratum: Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

Arthritis & Rheumatism ◽

10.1002/art.27747 ◽

2010 ◽

Vol 62 (10) ◽

pp. 3130-3130 ◽

Cited By ~ 2

Author(s):

Joel Kremer ◽

Christopher Ritchlin ◽

Alan Mendelsohn ◽

Daniel Baker ◽

Lilianne Kim ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text